BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 24965297)

  • 1. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
    Opatrna S; Popperlova A; Kalousová M; Zima T
    Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
    Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
    Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
    Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
    BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G; Del Turco S; Navarra T; Lee WM;
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
    Schmitt CP; von Heyl D; Rieger S; Arbeiter K; Bonzel KE; Fischbach M; Misselwitz J; Pieper AK; Schaefer F;
    Nephrol Dial Transplant; 2007 Jul; 22(7):2038-44. PubMed ID: 17420168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
    Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
    Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
    Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
    Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
    Schwenger V; Morath C; Salava A; Amann K; Seregin Y; Deppisch R; Ritz E; Bierhaus A; Nawroth PP; Zeier M
    J Am Soc Nephrol; 2006 Jan; 17(1):199-207. PubMed ID: 16319192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAGE expression in the human peritoneal membrane.
    Kihm LP; Wibisono D; Müller-Krebs S; Pfisterer F; Morath C; Gross ML; Morcos M; Seregin Y; Bierhaus A; Nawroth PP; Zeier M; Schwenger V
    Nephrol Dial Transplant; 2008 Oct; 23(10):3302-6. PubMed ID: 18477569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.
    Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
    Perit Dial Int; 2000; 20(6):643-51. PubMed ID: 11216553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.
    Lai KN; Leung JC; Chan LY; Li FF; Tang SC; Lam MF; Tse KC; Yip TP; Chan TM; Wieslander A; Vlassara H
    Clin Exp Immunol; 2004 Dec; 138(3):466-75. PubMed ID: 15544624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.
    Boulanger E; Wautier MP; Wautier JL; Boval B; Panis Y; Wernert N; Danze PM; Dequiedt P
    Kidney Int; 2002 Jan; 61(1):148-56. PubMed ID: 11786095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1.
    Pullerits R; Brisslert M; Jonsson IM; Tarkowski A
    Arthritis Rheum; 2006 Dec; 54(12):3898-907. PubMed ID: 17133598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the -374T/A receptor of advanced glycation end products gene polymorphism and peritoneal solute transport status at the initiation of peritoneal dialysis.
    Maruyama Y; Numata M; Nakayama M; Matsuo N; Nordfors L; Hosoya T; Lindholm B
    Ther Apher Dial; 2007 Aug; 11(4):301-5. PubMed ID: 17661837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo.
    van Zoelen MA; Yang H; Florquin S; Meijers JC; Akira S; Arnold B; Nawroth PP; Bierhaus A; Tracey KJ; van der Poll T
    Shock; 2009 Mar; 31(3):280-4. PubMed ID: 19218854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human RAGE antibody protects against AGE-mediated podocyte dysfunction.
    Müller-Krebs S; Kihm LP; Madhusudhan T; Isermann B; Reiser J; Zeier M; Schwenger V
    Nephrol Dial Transplant; 2012 Aug; 27(8):3129-36. PubMed ID: 22510380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products.
    Boulanger E; Wautier MP; Gane P; Mariette C; Devuyst O; Wautier JL
    Nephrol Dial Transplant; 2004 Sep; 19(9):2208-16. PubMed ID: 15213320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis.
    Loeser RF; Yammani RR; Carlson CS; Chen H; Cole A; Im HJ; Bursch LS; Yan SD
    Arthritis Rheum; 2005 Aug; 52(8):2376-85. PubMed ID: 16052547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.